Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Blood

• Publication date

  2001-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V97.10.3197PMID 11342449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines

  2000cited by this paper
• The Myeloid-specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2*

  1999cited by this paper
• Acute myeloid leukemia.

  1999cited by this paper
• The sialoadhesin CD33 is a myeloid‐specific inhibitory receptor

  1999cited by this paper
• Antibody-targeted therapy for myeloid leukemia.

  1999cited by this paper
• Drug-induced immune thrombocytopenia: an overview of pathogenesis.

  1999cited by this paper
• Action of DNA repair endonuclease ERCC1/XPF in living cells.

  1999cited by this paper
• Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.

  1998cited by this paper
• Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.

  1998cited by this paper
• Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

  1996cited by this paper
• A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.

  1995cited by this paper
• Effect of thyroid hormones and other iodinated compounds on the transition of monocytes into veiled/dendritic cells: role of granulocyte-macrophage colony-stimulating factor, tumour-necrosis factor-α and interleukin-6

  1994cited by this paper
• A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.

  1994cited by this paper
• Effect of thyroid hormones and other iodinated compounds on the transition of monocytes into veiled/dendritic cells: role of granulocyte-macrophage colony-stimulating factor, tumour-necrosis factor-alpha and interleukin-6.

  1994cited by this paper
• Chemistry and biology of natural and designed enediynes.

  1993cited by this paper
• Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis.

  1993cited by this paper
• CD45 Gating for Routine Flow Cytometric Analysis of Human Bone Marrow Specimens

  1993cited by this paper
• Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model.

  1992cited by this paper
• Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.

  1992cited by this paper
• A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.

  1991cited by this paper
• Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically.

  1988cited by this paper
• Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen.

  1988cited by this paper
• Expression of normal myeloid-associated antigens by acute leukemia cells.

  1986cited by this paper
• Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome.

  1985cited by this paper
• A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.

  1984cited by this paper
• Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester.

  1979cited by this paper

• Synthetic peptide hydrogels as a model of the bone marrow niche demonstrate efficacy of a combined CRISPR-CAR T-cell therapy for acute myeloid leukaemia

  2025cites this paper
• Trogocytosis-mediated immune evasion in the tumor microenvironment

  2025cites this paper
• Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.

  2024cites this paper
• Intercellular Transfer of Immune Regulatory Molecules Via Trogocytosis.

  2024cites this paper
• CD37 in acute myeloid leukemia: a novel surface target for drug delivery

  2024cites this paper
• A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

  2024cites this paper
• Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index.

  2024cites this paper
• [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].

  2023cites this paper
• Inhibitory innate receptors and their potential role in transplantation.

  2023cites this paper
• Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers

  2023cites this paper
• Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

  2023cites this paper
• Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia

  2023cites this paper
• Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions

  2023cites this paper
• Glycomimetics for the inhibition and modulation of lectins

  2023cites this paper
• Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

  2023cites this paper
• Gemtuzumab Ozogamicin: A Drug Used to Treat Acute Myeloid Leukemia

  2022cites this paper
• Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis

  2022cites this paper
• A Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug Payloads

  2022cites this paper
• Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

  2022cites this paper
• Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?

  2022cites this paper
• Antibody-Drug Conjugates in Myeloid Leukemias.

  2022cites this paper
• GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance

  2022cites this paper
• Antibody drug conjugates: The dos and don'ts in clinical development.

  2022cites this paper
• A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

  2022cites this paper
• Emerging new therapeutic antibody derivatives for cancer treatment

  2022cites this paper
• FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis

  2022cites this paper
• The clinical development of antibody–drug conjugates — lessons from leukaemia

  2021cites this paper
• Siglecs as Therapeutic Targets in Cancer

  2021cites this paper
• Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?

  2021cites this paper
• SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells

  2021cites this paper
• Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates

  2021cites this paper
• CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

  2021cites this paper
• The role of allergen‐specific IgE, IgG and IgA in allergic disease

  2021cites this paper
• Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved ADCs—A Necessity for Future ADC Research and Development

  2021cites this paper
• Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

  2021cites this paper
• Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin

  2021cites this paper
• Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021

  2021cites this paper
• Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

  2021cites this paper
• Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone.

  2021cites this paper
• The role of IgE, IgG, and IgA in tolerance, sensitization, and targeted treatment of allergic disease

  2021cites this paper
• Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.

  2020cites this paper
• Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.

  2020cites this paper
• Conventional and Nonconventional Approaches to Site-Specific Targeting of Nanotherapeutics in Some Infectious Diseases and Metabolic Disorders

  2020cites this paper
• Advances of Nanoparticles for Leukemia Treatment.

  2020cites this paper
• An overview of antibody–drug conjugates in oncological practice

  2020cites this paper
• Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

  2020cites this paper
• Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery

  2020cites this paper
• Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and feature.

  2020cites this paper
• CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110

  2020cites this paper
• Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

  2020cites this paper
• Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.

  2020cites this paper
• Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults

  2020cites this paper
• Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33

  2020cites this paper
• The optimal dosing of gemtuzumab ozagamicin: where to go from here?

  2019cites this paper
• The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.

  2019cites this paper
• Detection of CD33 expression on monocyte surface is influenced by phagocytosis and temperature.

  2019cites this paper
• A personalized approach to acute myeloid leukemia therapy: current options

  2019cites this paper
• General Physiology and Biophysics Revised manuscript #2 Title: Detection of CD33 Expression on Monocyte Surface is Influenced by Phagocytosis and Temperature Running title: CD33 Expression on Monocytes

  2019cites this paper
• A personalized approach to acute myeloid leukemia therapy: current options

  2019cites this paper
• Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

  2019cites this paper
• Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin

  2019cites this paper
• Human Monoclonal Antibodies: Methods and Protocols

  2019cites this paper
• The optimal dosing of gemtuzumab ozagamicin: where to go from here?

  2019cites this paper
• Metadichol® and CD33 expression in Umbilical Cord Cells

  2019cites this paper
• ADCs on the Market and in Clinical Development

  2019cites this paper
• Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

  2019cites this paper
• Challenges and new frontiers in analytical characterization of antibody-drug conjugates

  2018cites this paper
• Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy

  2018cites this paper
• Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia

  2018cites this paper
• Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia

  2018cites this paper
• Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

  2018cites this paper
• Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies

  2018cites this paper
• Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

  2018cites this paper
• Unraveling novel genes that are essential for acute myeloid leukemia and normal hematopoiesis

  2018cites this paper
• Chimeric Antigen Receptor-Engineered T Cell Therapy in Acute Myeloid Leukaemia

  2018cites this paper
• Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia

  2018cites this paper
• Streamlined Total Synthesis of Shishijimicin A and Its Application to the Design, Synthesis, and Biological Evaluation of Analogues thereof and Practical Syntheses of PhthNSSMe and Related Sulfenylating Reagents.

  2018cites this paper
• Construction and Expression of Transmembrane and Secretory Recombinant Human CD 33 Extracellular Domain in HEK 293 F Cell

  2018cites this paper
• Development of a novel T cell engaging antibody derivative for local PD-1/PD-L1 immune checkpoint blockade in acute myeloid leukemia

  2018cites this paper
• Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.

  2017cites this paper
• Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.

  2017cites this paper
• Ligand-Targeted Drug Delivery.

  2017cites this paper
• Acute myeloid leukemia targets for bispecific antibodies

  2017cites this paper
• Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.

  2017cites this paper
• Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia

  2017cites this paper
• Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?

  2017cites this paper
• Gemtuzumab ozogamicin for acute myeloid leukemia.

  2017cites this paper
• Treatment of Elderly Patients With Acute Myeloid Leukemia

  2017cites this paper
• Emerging therapies for acute myeloid leukemia: translating biology into the clinic.

  2017cites this paper
• Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia

  2017cites this paper
• SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells

  2017cites this paper
• Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia

  2016cites this paper
• Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates.

  2016cites this paper
• HOXA-activated early T-cell progenitor acute lymphoblastic leukemia: predictor of poor outcome?

  2016cites this paper
• The optimal dosing of gemtuzumab ozagamicin: where to go from here?

  2016cites this paper
• Detection of mSiglec-E, in solution and expressed on the surface of Chinese hamster ovary cells, using sialic acid functionalised gold nanoparticles.

  2016cites this paper
• The safety of treatment options for elderly people with acute myeloid leukemia

  2016cites this paper
• Antibody-drug conjugates as drug carrier systems for bioactive agents

  2016cites this paper
• Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.

  2016cites this paper
• Antibody–drug conjugates for targeted anticancer drug delivery

  2016cites this paper